U.S. Prospective MFN Pricing Could Balance Drug Costs and Innovation

The United States faces ongoing challenges related to pharmaceutical pricing disparities, with Americans paying significantly higher prices for prescription drugs compared to peer countries. This discrepancy largely results from many foreign governments setting drug prices well below U.S. levels, often covering only manufacturing costs and relying on the U.S. market to offset high research and development (R&D) expenses. The heavy U.S. burden has spurred policy efforts to encourage other developed nations to increase their contributions to drug R&D costs, aiming to reduce U.S. prices without undermining innovation. A key proposal to address this issue is the adoption of a prospective most-favored-nation (MFN) pricing strategy for brand-name drugs. Unlike retrospective MFN models that retrospectively apply foreign prices to the U.S. market, prospective MFN aims to set prices for new drugs with an eye towards balancing global revenue by nudging foreign prices upward while lowering U.S. prices. This dynamic leverages manufacturers’ negotiations to prevent foreign countries from enforcing unsustainably low prices that could threaten drug innovation. Retrospective MFN pricing sets U.S. prices based on existing foreign prices, often imposing strict price ceilings that reduce manufacturers’ revenues and risk diminishing investments in early-stage R&D. This approach also fails to incentivize foreign countries to pay more and could accelerate biopharmaceutical innovation shifting to competing markets such as China. In contrast, prospective MFN policies provide manufacturers with negotiation leverage for new drugs, signaling that foreign price demands influence U.S. pricing and potential patient access. This forward-looking approach preserves global revenue streams necessary for sustaining innovation and helps maintain U.S. leadership in pharmaceutical development. Recent policy implementations include voluntary MFN pricing agreements with major pharmaceutical companies like Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk. These agreements extend MFN pricing models to state Medicaid programs through the CMS Innovation Center’s "GENEROUS" model, which uses a carefully selected basket of economically similar countries to set price benchmarks. This model employs the second-lowest net price from selected peer countries, adjusted by GDP per capita, to establish U.S. Medicaid prices. The GENEROUS model includes mandatory negotiation of supplemental rebates by participating manufacturers to achieve alignment with international prices. States maintain discretion over coverage decisions, allowing flexibility in adopting MFN pricing when beneficial. Ensuring the success of prospective MFN pricing also depends on robust protection of intellectual property rights to prevent foreign governments from circumventing pricing agreements through regulatory actions or forced IP transfers. The European Union’s consideration of compulsory licenses for patent use during crises highlights the need for U.S. vigilance to protect innovation incentives. Comparability among reference countries is crucial; thus, the policy advocates selecting OECD member countries with economic size and development levels aligned closely with the U.S., excluding lower income economies to prevent pricing distortions. Overall, the prospective MFN pricing framework presents a more balanced and sustainable solution to pharmaceutical pricing disparities. It aims to lower costs for American patients, support fair global pricing, and preserve incentives critical to continued biomedical innovation.